The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Open accessAbstract
IDH1 and IDH2 mutations occur frequently in gliomas and acute myeloid leukemia, leading to simultaneous loss and gain of activities in the production of α-ketoglutarate (α-KG) and 2-hydroxyglutarate (2-HG), respectively. Here we demonstrate that 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. 2-HG occupies the same space as α-KG does in the active site of histone demethylases. Ectopic expression of tumor-derived IDH1 and IDH2 mutants inhibits histone demethylation and 5mC hydroxylation. In glioma, IDH1 mutations are associated with increased histone methylation and decreased 5-hydroxylmethylcytosine (5hmC). Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
In the citing paper
“The observation that IDH1 and IDH2 mutations can partially phenocopy the loss of TET function may explain the mutual exclusivity of these mutations in cancer 95,97 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [97]
In the citing paper
“Mutant IDH protein is a competitive inhibitor of hydroxylases, including the TET family of 5mC hydroxylases120–122.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [122]
In the citing paper
“These observations support a model in which PU.1 guides TET2 to a specific subset of genomic regions to facilitate the oxidation of 5mC to 5hmC, a reaction that is inhibited by 2-hydroxyglutarate47 and enhanced by vitamin C13 (Figure 5d).”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [47]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“Furthermore, TH17 cell differentiation could be initiated by exogenous addition of D-2-HG to naïve CD4+ T cells or by genetic silencing of TET1 and TET2, established targets of 2-HG143-145.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 2×
“HIF-1a is a transcription factor whose function is linked to metabolism, angiogenesis and tumorigenesis, and whose protein level is downregulated under normoxic conditions by PHD-mediated hydroxylation and subsequent hydroxylation-targeted ubiquitination (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2…”
Self-citationEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Research works printed but not linked: 1
- Han, 2007, Structural basis for histone demethylation by JHDM1, Frontier Science, 1, 52
Cited by
Sorted by citations
Items 201–300 of 1,006
TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases
Hsu, C.-H., Peng, K.-L., Kang, M.-L., Chen, Y.-R., Yang, Y., Tsai, C.-H., Chu, C.-S., Jeng, Y., Chen, Y.-T., Lin, F.-M., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.030 · Cited by 283
Self-citationCaveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms
Sotgia, F., Martinez‐Outschoorn, U., Howell, A., Pestell, R. G., Pavlides, S., & Lisanti, M. P. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-120856 · Cited by 290
Grassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0772-t · Cited by 280
Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription
Boukouris, A. E., Zervopoulos, S. D., & Michelakis, E. D. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.05.013 · Cited by 289
TET (Ten-eleven translocation) family proteins: structure, biological functions and applications
Zhang, X., Zhang, Y., Wang, C., & Wang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01537-x · Cited by 297
Self-citationJia, D., Park, J. E., Jung, K., Levine, H., & Kaipparettu, B. A. (2018) · Cells · doi:10.3390/cells7030021 · Cited by 283
Mellinghoff, I. K., Peñas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Jankú, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0611 · Cited by 291
The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks
Ivan, M., & Kaelin, W. G. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.002 · Cited by 273
The functional roles of TCA cycle metabolites in cancer
Eniafe, J., & Jiang, S. (2021) · Oncogene · doi:10.1038/s41388-020-01639-8 · Cited by 289
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C. E., Rutka, J. T., & Zadeh, G. M. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 293
Functions of the sirtuin deacylase SIRT5 in normal physiology and pathobiology
Kumar, S., & Lombard, D. B. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1458071 · Cited by 273
Revisiting the TCA cycle: signaling to tumor formation
Raimundo, N., Baysal, B. E., & Shadel, G. S. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.001 · Cited by 281
Cancer stem cells (CSCs): metabolic strategies for their identification and eradication
Francesco, E. M. D., Sotgia, F., & Lisanti, M. P. (2018) · Biochemical Journal · doi:10.1042/bcj20170164 · Cited by 274
Núñez, F. J., Mendez, F., Kadiyala, P., Alghamri, M. S., Savelieff, M. G., Garcia-Fabiani, M. B., Haase, S., Koschmann, C. J., Calinescu, A., Kamran, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1427 · Cited by 264
L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH
Intlekofer, A. M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A. S., Salah, S., Gunner, M. R., Chodera, J. D., Cross, J. R., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2307 · Cited by 268
Self-citationRampal, R. K., Akalin, A., Madžo, J., Vasanthakumar, A., Pronier, E., Patel, J. L., Li, Y., Ahn, J., Abdel-Wahab, O. I., Shih, A. H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.004 · Cited by 280
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
Simon, C., Chagraoui, J., Krosl, J., Gendron, P., Wilhelm, B., Lemieux, S., Boucher, G., Chagnon, P., Drouin, S., Lambert, R., et al. (2012) · Genes & Development · doi:10.1101/gad.186411.111 · Cited by 264
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. Q. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 266
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
Santagata, S., Eberlin, L. S., Norton, I. H., Calligaris, D., Feldman, D. R., Ide, J. L., Liu, X., Wiley, J. S., Vestal, M. L., Ramkissoon, S. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404724111 · Cited by 264
Caveolin-1 in the regulation of cell metabolism: a cancer perspective
Nwosu, Z. C., Ebert, M., Dooley, S., & Meyer, C. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0558-7 · Cited by 257
Dimou, A. D., Tsimihodimos, V., & Bairaktari, E. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074022 · Cited by 274
5‐Hydroxymethylcytosine, the Sixth Base of the Genome
Münzel, M., Globisch, D., & Carell, T. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101547 · Cited by 252
IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma
Wang, C., McKeithan, T. W., Gong, Q., Zhang, W., Bouska, A. C., Rosenwald, A., Gascoyne, R. D., Wu, X., Wang, J., Muhammad, Z., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644591 · Cited by 256
Defects in mitochondrial metabolism and cancer
Gaude, E., & Frezza, C. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-10 · Cited by 266
Leukemic stem cells and therapy resistance in acute myeloid leukemia
Stelmach, P., & Trumpp, A. (2023) · Haematologica · doi:10.3324/haematol.2022.280800 · Cited by 273
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 263
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Abdel-Wahab, O. I., & Levine, R. L. (2013) · Blood · doi:10.1182/blood-2013-01-451781 · Cited by 261
Pollyea, D. A., Tallman, M. S., de Botton, S., Kantarjian, H. M., Collins, R. H., Stein, A. S., Frattini, M. G., Xu, Q., Tosolini, A., See, W. L., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0472-2 · Cited by 253
Notch signaling: switching an oncogene to a tumor suppressor
Lobry, C., Oh, P., Mansour, M. R., Look, A. T., & Aifantis, I. (2014) · Blood · doi:10.1182/blood-2013-08-355818 · Cited by 258
Miller, J. J., Castro, L. N. G., McBrayer, S. K., Weller, M., Cloughesy, T. F., Portnow, J., Andronesi, O. C., Barnholtz‐Sloan, J. S., Baumert, B. G., Berger, M. S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac207 · Cited by 265
Detection and analysis of chiral molecules as disease biomarkers
Liu, Y., Wu, Z., Armstrong, D. W., Wolosker, H., & Zheng, Y. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00476-z · Cited by 261
Self-citationEpigenetic encoding, heritability and plasticity of glioma transcriptional cell states
Chaligné, R., Gaiti, F., Silverbush, D., Schiffman, J. S., Weisman, H. R., Kluegel, L., Gritsch, S., Deochand, S. D., Castro, L. N. G., Richman, A. R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00927-7 · Cited by 247
Mellinghoff, I. K., Lu, M., Wen, P. Y., Taylor, J. W., Maher, E. A., Arrillaga‐Romany, I., Peters, K. B., Ellingson, B. M., Rosenblum, M. K., Chun, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02141-2 · Cited by 256
Li, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.017 · Cited by 244
Self-citationMetabolic rearrangements in primary liver cancers: cause and consequences
Satriano, L., Lewińska, M., Rodrigues, P. M., Bañales, J. M., & Andersen, J. B. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0217-8 · Cited by 245
Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
Ye, D., Guan, K.-L., & Xiong, Y. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.005 · Cited by 242
Self-citationWild-type and mutated IDH1/2 enzymes and therapy responses
Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W., & Noorden, C. J. F. V. (2018) · Oncogene · doi:10.1038/s41388-017-0077-z · Cited by 249
Multifaceted role of branched-chain amino acid metabolism in cancer
Peng, H., Wang, Y., & Luo, W. (2020) · Oncogene · doi:10.1038/s41388-020-01480-z · Cited by 244
Sorting out functions of sirtuins in cancer
Roth, M., & Chen, W. (2013) · Oncogene · doi:10.1038/onc.2013.120 · Cited by 242
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.008 · Cited by 241
Cancer epigenetics in clinical practice
Dávalos, V., & Esteller, M. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21765 · Cited by 251
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer
Hua, W., ten Dijke, P., Kostidis, S., Giera, M. A., & Hornsveld, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03398-6 · Cited by 245
Yang, Q., Liang, X., Sun, X., Zhang, L., Fu, X., Rogers, C. J., Berim, A., Zhang, S., Wang, S., Wang, B., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.010 · Cited by 237
Self-citationDNA methylation disruption reshapes the hematopoietic differentiation landscape
Izzo, F., Lee, S. C., Poran, A., Chaligne, R., Gaiti, F., Gross, B., Murali, R. R., Deochand, S. D., Ang, C., Jones, P. W., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0595-4 · Cited by 236
Kalyanaraman, B., Cheng, G., Hardy, M., Ouari, O., López, M., Joseph, J., Zielonka, J., & Dwinell, M. B. (2017) · Redox Biology · doi:10.1016/j.redox.2017.09.020 · Cited by 239
Epigenetics of Aging and Aging-Associated Diseases
Saul, D., & Kosinsky, R. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010401 · Cited by 247
Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond
Guo, J. U., Su, Y., Zhong, C., Ming, G.-L., & Song, H. (2011) · Cell Cycle · doi:10.4161/cc.10.16.17093 · Cited by 235
2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling
Fu, X., Chin, R., Vergnes, L., Hwang, H., Deng, G., Xing, Y., Pai, M. Y., Li, S., Ta, L. H., Fazlollahi, F., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.009 · Cited by 230
TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation
Cimmino, L., Abdel-Wahab, O. I., Levine, R. L., & Aifantis, I. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.08.007 · Cited by 237
Stein, E. M., Dinardo, C. D., Fathi, A. T., Mims, A. S., Pratz, K. W., Savona, M. R., Stein, A. S., Stone, R. M., Winer, E. S., Seet, C. S., et al. (2020) · Blood · doi:10.1182/blood.2020007233 · Cited by 237
Waarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 249
Metabolic regulation of chromatin modifications and gene expression
Schvartzman, J. M., Thompson, C. B., & Finley, L. W. S. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201803061 · Cited by 233
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Golub, D., Iyengar, N. S., Dogra, S., Wong, T., Bready, D., Tang, K., Modrek, A. S., & Placantonakis, D. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00417 · Cited by 234
2-Oxoglutarate-dependent dioxygenases in cancer
Losman, J.-A., Koivunen, P., & Kaelin, W. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00303-3 · Cited by 241
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
Xu, Y., Lv, L., Liu, Y., Smith, M. D., Li, W., Tan, X. M., Cheng, M., Li, Z., Bovino, M., Aubé, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129317 · Cited by 230
Self-citationItaconate inhibits TET DNA dioxygenases to dampen inflammatory responses
Chen, L., Morcelle, C., Cheng, Z., Chen, X., Xu, Y., Gao, Y., Song, J., Li, Z., Smith, M. D., Shi, M., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00853-8 · Cited by 234
Self-citationChang, S., Yim, S., & Park, H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228
Grasso, D., Zampieri, L. X., Capelôa, T., de Velde, J. A. V., & Sonveaux, P. (2020) · Cell Stress · doi:10.15698/cst2020.06.221 · Cited by 239
The crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · The EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 235
Turkalp, Z. T., Karamchandani, J., & Das, S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1205 · Cited by 222
Zdzisińska, B., Żurek, A., & Kandefer-Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0406-x · Cited by 221
The epigenetic role of vitamin C in health and disease
Camarena, V., & Wang, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2145-x · Cited by 227
Cancer Cell MetabolismPreprint
Cairns, R. A., Harris, I. S., McCracken, S. A., & Mak, T. W. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.012856 · Cited by 229
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
Oncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 216
Chromatin signatures of cancerPreprint
Morgan, M. A., & Shilatifard, A. (2015) · Genes & Development · doi:10.1101/gad.255182.114 · Cited by 218
The Mitochondrion as an Emerging Therapeutic Target in Cancer
Roth, K. G., Mambetsariev, I., Kulkarni, P., & Salgia, R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.009 · Cited by 219
MethylSig: a whole genome DNA methylation analysis pipeline
Park, Y., Figueroa, M. E., Rozek, L. S., & Sartor, M. A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu339 · Cited by 218
Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer
Hayashi, Y., Yokota, A., Harada, H., & Huang, G. (2019) · Cancer Science · doi:10.1111/cas.13990 · Cited by 229
Molecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism
Somasundaram, V., Basudhar, D., Bharadwaj, G., No, J. H., Ridnour, L. A., Cheng, R. Y. S., Fujita, M., Thomas, D. D., Anderson, S. K., McVicar, D. W., et al. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7527 · Cited by 217
Cancer metabolism in space and time: Beyond the Warburg effect
Danhier, P., Bański, P., Payen, V. L., Grasso, D., Ippolito, L., Sonveaux, P., & Porporato, P. E. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.02.001 · Cited by 230
Comparison of glioblastoma (GBM) molecular classification methods
Lee, E., Yong, R. L. M., Paddison, P. J., & Zhu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.07.006 · Cited by 219
Undercover: gene control by metabolites and metabolic enzymesPreprint
van der Knaap, J. A., & Verrijzer, C. P. (2016) · Genes & Development · doi:10.1101/gad.289140.116 · Cited by 222
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491571 · Cited by 210
Lactate dehydrogenase A silencing in IDH mutant gliomas
Chesnelong, C., Chaumeil, M. M., Blough, M. D., Al-Najjar, M., Stechishin, O. D., Chan, J. A., Pieper, R. O., Ronen, S. M., Weiss, S., Luchman, H. A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not243 · Cited by 210
Choe, S. E., Wang, H., Dinardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Watts, J. M., Pollyea, D. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001503 · Cited by 218
Stable isotope-resolved metabolomics and applications for drug development
Fan, T. W. ‐., Lorkiewicz, P., Sellers, K., Moseley, H., Higashi, R. M., & Lane, A. N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.007 · Cited by 215
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
Clark, O., Yen, K. E., & Mellinghoff, I. K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1333 · Cited by 210
FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms
Azzam, S. K., AlSafar, H. S., & Sajini, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073800 · Cited by 211
Wang, P., Wu, J., Ma, S., Zhang, L., Yao, J., Hoadley, K. A., Wilkerson, M. D., Perou, C. M., Guan, K.-L., Ye, D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.029 · Cited by 206
Self-citation5-hydroxymethylcytosine and its potential roles in development and cancer
Pfeifer, G. P., Kadam, S., & Jin, S. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-10 · Cited by 205
Acute loss of TET function results in aggressive myeloid cancer in mice
An, J., González‐Avalos, E., Chawla, A., Jeong, M., López-Moyado, I. F., Li, W., Goodell, M. A., Chávez, L., Ko, M., & Rao, A. (2015) · Nature Communications · doi:10.1038/ncomms10071 · Cited by 215
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Popovici-Müller, J. V., Saunders, J. O., Salituro, F. G., Travins, J. M., Yan, S., Zhao, F., Größ, S., Dang, L., Yen, K. E., Yang, H., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300225h · Cited by 204
Self-citationDang, L., & Su, S.-S. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044732 · Cited by 204
How to stomach an epigenetic insult: the gastric cancer epigenome
Padmanabhan, N., Ushijima, T., & Tan, P. B. O. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.53 · Cited by 209
Ge, T., Gu, X., Jia, R., Ge, S., Chai, P., Zhuang, A., & Fan, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12374 · Cited by 220
TET proteins and 5‐methylcytosine oxidation in hematological cancers
Ko, M., An, J., Pastor, W. A., Koralov, S. B., Rajewsky, K., & Rao, A. (2014) · Immunological Reviews · doi:10.1111/imr.12239 · Cited by 202
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d -2-Hydroxyglutarate
Fan, J., Teng, X., Liu, L., Mattaini, K. R., Looper, R., Heiden, M. G. V., & Rabinowitz, J. D. (2014) · ACS Chemical Biology · doi:10.1021/cb500683c · Cited by 206
Self-citationChemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Lu, Y., Kwintkiewicz, J., Liu, Y., Tech, K., Frady, L. N., Su, Y.-T., Bautista, W., Moon, S. I., Macdonald, J. M., Ewend, M. G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2773 · Cited by 208
Self-citationMitochondrial complex III is necessary for endothelial cell proliferation during angiogenesis
Diebold, L. P., Gil, H. J., Gao, P., Martinez, C. A., Weinberg, S. E., & Chandel, N. S. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0011-x · Cited by 200
Characterizing DNA methylation alterations from The Cancer Genome Atlas
Weisenberger, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69740 · Cited by 200
Xiao, L., Hu, Z., Dong, X., Tan, Z. W., Li, W., Tang, M., Chen, L., Yang, L., Tao, Y., Jiang, Y., et al. (2014) · Oncogene · doi:10.1038/onc.2014.32 · Cited by 197
Yu, Y., Cui, Y., Niedernhofer, L. J., & Wang, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00265 · Cited by 200
Cytokine-like Roles for Metabolites in Immunity
Zasłona, Z., & O'Neill, L. A. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.002 · Cited by 202
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Quek, L. S., David, M. D., Kennedy, A., Metzner, M., Amatangelo, M. D., Shih, A. H., Stoilova, B., Quivoron, C., Heiblig, M., Willekens, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0115-6 · Cited by 199
Moonlighting functions of metabolic enzymes and metabolites in cancer
Pan, C., Li, B., & Simon, M. C. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.031 · Cited by 198
Role of mitochondrial alterations in human cancer progression and cancer immunity
Wang, S., Tseng, L., & Lee, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00956-w · Cited by 225
Targeting histone lysine demethylases — Progress, challenges, and the future
Thinnes, C. C., England, K. S., Kawamura, A., Chowdhury, R., Schofield, C. J., & Hopkinson, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.05.009 · Cited by 198
Molecular and cellular heterogeneity: the hallmark of glioblastoma
Aum, D. J., Kim, D. H., Beaumont, T., Leuthardt, E. C., Dunn, G. P., & Kim, A. H. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14521 · Cited by 200
Metadata
- Authors
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., Liu, L.-X., Jiang, W.-Q., Liu, J., Zhang, J.-Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.-H., Lei, Q.-Y., Guan, K.-L., Zhao, S.-M., & Xiong, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- University of North Carolina at Chapel Hill (US)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Guan, Kun-Liang
- Xiong, Yue
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 19
- Issue
- 1
- Pages
- 17-30
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3229304
- OpenAlex
- W2131860315
- Cited by
- 2,875
- References
- 55
- Citations by year
- 2026: 165 · 2025: 168 · 2024: 192 · 2023: 182 · 2022: 183 · 2021: 270 · 2020: 214 · 2019: 191 · 2018: 195 · 2017: 183 · 2016: 196 · 2015: 180 · 2014: 183 · 2013: 157 · 2012: 137
- FWCI
- 90.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 928 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Natural Science Foundation of China (11079016, 30600112, 30871255, 30971485/C0706)
- Ministry of Education of the People's Republic of China
- National Key Research and Development Program of China (2011CB910600, 2011CB965300)
- Project 985
- Major State Basic Research Development Program of China (2009CB918401, 2009CB918600)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate-dependent dioxygenase, IDH1 mutation, IDH2 mutation, histone demethylase, 5-hydroxymethylcytosine, competitive inhibition, glioma, acute myeloid leukemia, DNA methylation, histone methylation, active site
- MeSH terms
- Animals, Binding, Competitive, Cytosine, DNA-Binding Proteins, Glioma, Glutarates, Histones, Humans, Mixed Function Oxygenases, Isocitrate Dehydrogenase, Ketoglutaric Acids, Models, Molecular, Oxalates, Oxidoreductases, N-Demethylating, Procollagen-Proline Dioxygenase, Proto-Oncogene Proteins, Gene Expression, Caenorhabditis elegans, Homeodomain Proteins, Amino Acid Substitution, Catalytic Domain, Caenorhabditis elegans Proteins, Endostatins, 5-Methylcytosine, F-Box Proteins, Cell Line, Tumor, Dioxygenases, Hypoxia-Inducible Factor 1, alpha Subunit, Biocatalysis, Histone Demethylases, Jumonji Domain-Containing Histone Demethylases, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
